Drugs / dHER2 + AS15 ASCI
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00952692 | Jul 2009 → Jul 2011 | breast cancer | Michael Morse, MD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dHER2 + AS15 ASCI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00952692 ↗ |
| Modality | Vaccine | “HER2-based cancer vaccine” PMID 22325452 ↗ Feb 2012 |
| Route | Intramuscular | “Patients will receive dHER2 ASCI injections IM” NCT00952692 ↗ |